Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Piperacillin/Tazobactam Versus Carbapenems in Non-bacteremic Urinary Tract Infections Due to Extended-spectrum Β-lactamase (ESBL)-producing Escherichia Coli or Klebsiella Pneumoniae - (CAPITIS Study)

NCT03891433 is registered in ClinicalTrials.gov with Universidad del Norte as lead sponsor.

NCT NCT03891433
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03891433 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Piperacillin/Tazobactam Versus Carbapenems in Non-bacteremic Urinary Tract Infections Due to Extended-spectrum Β-lactamase (ESBL)-producing Escherichia Coli or Klebsiella Pneumoniae - (CAPITIS Study)
Lead sponsor
Universidad del Norte
Phase
Phase 4
Overall status
Suspended
Start date
April 1, 2019
Completion date
April 1, 2026
Enrollment
198 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

carbapenem, clinical trial, drug resistance, bacterial, enterobacteriaceae infections, escherichia coli infection, infection due to esbl bacteria, klebsiella pneumoniae infection, urinary tract infections